Company profile
Bio-Techne Corporation
NASDAQ: TECH · Healthcare · Biotechnology
#140 of 1,417 Healthcare companies by revenue49th-percentile growth
EA Score
85AFH 89DQ 90GM 60SS 95
v0.1 · 65/100 weight · provisional
↑ Piotroski F, listing tenure · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$1.2B
Rev growth YoY (TTM)
+0.2%
Net income (FY)
$73.4M
Employees
3,100
as of 2026-08-06
Market cap
$11.3B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.2B$1.2B2025
Net income$73.4M$73.4M2025
Operating income$102.3M$102.3M2025
Total assets$2.6B$2.6B2025
Equity$1.9B$1.9B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Consumables88%
Instruments10%
Royalty2%
By geography
U S56%
Europe22%
C N8%
APAC, excluding Greater China6%
UNITED KINGDOM4%
Rest Of World3%
The read
What is Bio-Techne Corporation’s revenue?
Bio-Techne Corporation booked $1.2B in FY2025 revenue, growing 5.2% year over year — about the middle of the pack among Healthcare companies we track, at a 6.0% net margin.
Peers · Healthcare
Tempus AI, Inc.59CCuraleaf Holdings, Inc.49DIndivior Pharmaceuticals Inc67BExtendicare Inc.79B+Omnicell, Inc.78B+Trulieve Cannabis Corp.63CNeighbors
Hennepin →Key facts
CEOKim Kelderman
SectorHealthcare
IndustryBiotechnology
HeadquartersMinneapolis, MN
ExchangeNASDAQ: TECH
Employees3,100
IPO date1989-02-09
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.